Overview
- More than 70% of treated toddlers tolerated at least the equivalent of three to four peanut kernels after three years.
- No treatment-related anaphylaxis was reported, challenge reactions became milder over time, and skin irritation at the patch site declined.
- The analysis followed 91 children who had received placebo in an earlier trial before starting the Viaskin Peanut Patch for up to three years.
- The patch uses epicutaneous immunotherapy, delivering tiny amounts of peanut protein through the skin to train the immune system.
- Results were presented at the American College of Allergy, Asthma & Immunology meeting, the study was funded by DBV Technologies, the patch is not FDA-approved, and clinicians advise against home desensitization.